USTEKINUMAB

Search structure
Trade Names:
Synonyms:
Status: Approved (2009)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L04AC05
UNII: FU77B4U5Z0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Interleukin-12 inhibitor DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Psoriasis 4 D011565 ClinicalTrials
Crohn Disease 4 D003424 ClinicalTrials
Spondylitis, Ankylosing 3 D013167 ClinicalTrials
Lupus Erythematosus, Systemic 3 D008180 ClinicalTrials
Colitis, Ulcerative 3 D003093 ClinicalTrials
Dermatomyositis 3 D003882 ClinicalTrials
Pouchitis 3 D019449 ClinicalTrials
Colitis 3 D003092 ClinicalTrials
Takayasu Arteritis 3 D013625 ClinicalTrials
Hidradenitis Suppurativa 2 D017497 ClinicalTrials
Behcet Syndrome 2 D001528 ClinicalTrials
Multiple Sclerosis 2 D009103 ClinicalTrials
Giant Cell Arteritis 2 D013700 ClinicalTrials
Liver Cirrhosis, Biliary 2 D008105 ClinicalTrials
Arthritis, Rheumatoid 2 D001172 ClinicalTrials
Hematologic Neoplasms 2 D019337 ClinicalTrials
Pemphigoid, Bullous 2 D010391 ClinicalTrials
Diabetes Mellitus, Type 1 2 D003922 ClinicalTrials
Sarcoidosis 2 D012507 ClinicalTrials
Uveitis 2 D014605 ClinicalTrials
Dermatitis, Atopic 2 D003876 ClinicalTrials
Graft vs Host Disease 2 D006086 ClinicalTrials
Ichthyosis 0 D007057 ClinicalTrials

Side Effects from Label

Side effects Relative Frequency (%) Labels
Infections and infestations Nasopharyngitis
Infections and infestations Nasopharyngitis 8.0
Nervous system disorders Headache 5.0
Infections and infestations Upper respiratory tract infection
Infections and infestations Upper respiratory tract infection 5.0
General disorders and administration site conditions Asthenia 3.0
General disorders and administration site conditions Fatigue 3.0
Nervous system disorders Headache
General disorders and administration site conditions Asthenia
Gastrointestinal disorders Diarrhoea
Gastrointestinal disorders Diarrhoea 2.0
General disorders and administration site conditions Fatigue
Skin and subcutaneous tissue disorders Pruritus 2.0
Musculoskeletal and connective tissue disorders Back pain
Musculoskeletal and connective tissue disorders Back pain 1.0
Psychiatric disorders Depression
Psychiatric disorders Depression 1.0
Cardiac disorders Dizziness
Cardiac disorders Dizziness 1.0
General disorders and administration site conditions Injection site erythema
General disorders and administration site conditions Injection site erythema 1.0
Respiratory, thoracic and mediastinal disorders Laryngeal pain
Respiratory, thoracic and mediastinal disorders Laryngeal pain 1.0
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 1.0
Musculoskeletal and connective tissue disorders Myalgia
Musculoskeletal and connective tissue disorders Myalgia 1.0
Skin and subcutaneous tissue disorders Pruritus

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Infections and infestations
12.25
Skin and subcutaneous tissue disorders
10.2
Injury, poisoning and procedural complications
9.36
General disorders and administration site conditions
8.68
Respiratory, thoracic and mediastinal disorders
7.88
Immune system disorders
6.77
Gastrointestinal disorders
5.87
Nervous system disorders
5.6
Musculoskeletal and connective tissue disorders
4.69
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.44
Vascular disorders
3.82
Investigations
3.14
Cardiac disorders
2.58

Cross References

Resources Reference
CAS NUMBER 815610-63-0
ChEMBL CHEMBL1201835
FDA SRS FU77B4U5Z0
Guide to Pharmacology 6885
CONTENTS